Chemotherapy
Learning Objectives
By the end of this page, you should be able to:
- Classify chemotherapy drugs as cell-cycle-specific or cell-cycle-nonspecific and explain why this distinction guides dosing schedules.
- Describe the mechanism of action of alkylating agents, antimetabolites, and targeted therapy agents.
- Name the signature dose-limiting toxicity of major chemotherapy drugs (doxorubicin, vincristine, cisplatin, methotrexate, cyclophosphamide, bleomycin).
- Explain how rescue therapies (leucovorin, mesna, dexrazoxane) protect against specific drug toxicities.
- Differentiate traditional cytotoxic chemotherapy from targeted therapy and immunotherapy.
- Apply this knowledge to predict which chemotherapy toxicity a patient is likely experiencing based on their drug regimen and symptoms.
Quick Answer
Chemotherapy uses cytotoxic drugs to kill rapidly dividing cancer cells by damaging DNA, blocking DNA/RNA synthesis, or disrupting mitosis. Because these drugs can't perfectly distinguish cancer cells from other fast-dividing normal cells (bone marrow, GI mucosa, hair follicles), most chemotherapy toxicity is predictable from this shared biology — myelosuppression, mucositis, and alopecia are near-universal. Drugs are grouped as cell-cycle-specific (kill cells only in a particular phase — S-phase or M-phase) or cell-cycle-nonspecific (kill cells in any phase, including G0). This distinction determines whether a drug works best as a continuous infusion or a single bolus dose. Modern oncology increasingly pairs classic cytotoxics with targeted therapy (drugs aimed at a specific molecular abnormality in the tumor), which improves selectivity and reduces off-target damage.
Cell-Cycle Kinetics: The Organizing Principle
Before memorizing drug lists, understand why chemotherapy drugs are split into two big buckets. The cell cycle runs G1 → S (DNA synthesis) → G2 → M (mitosis) → back to G1, with resting cells parked in G0.
Cell-cycle-specific (CCS) agents only kill cells actively cycling through a particular phase:
- S-phase specific: antimetabolites (methotrexate, 5-fluorouracil, cytarabine, 6-mercaptopurine) — they sabotage DNA synthesis, so they only matter when the cell is actually replicating its DNA.
- M-phase specific: vinca alkaloids (vincristine, vinblastine) and taxanes (paclitaxel, docetaxel) — they jam the mitotic spindle, so they only matter when the cell is trying to divide.
Because CCS drugs need cells to pass through the vulnerable phase, they work best given as a continuous or repeated low-dose infusion — this "catches" more cells as they cycle through S or M phase over time, rather than hitting only the fraction of cells in that phase at one instant.
Cell-cycle-nonspecific (CCNS) agents damage DNA (or other targets) regardless of what phase the cell is in, including resting G0 cells:
- Alkylating agents (cyclophosphamide, cisplatin, busulfan)
- Anthracyclines (doxorubicin, daunorubicin)
- Topoisomerase inhibitors (etoposide, irinotecan)
CCNS drugs show a more classic dose-response curve — kill fraction rises with dose — so they're often given as a large single bolus dose with recovery time built in before the next cycle.
This is a favorite exam distinction: "why is this drug given as a 24-hour infusion instead of a push?" — the answer is almost always cell-cycle specificity.
Alkylating Agents
Definition: Alkylating agents attach alkyl groups to DNA (commonly at the N7 position of guanine), causing cross-links between DNA strands. This prevents the DNA helix from separating properly, which blocks replication and transcription and ultimately triggers apoptosis.
Explanation: Because the damage is to the DNA structure itself, alkylators don't need the cell to be in any particular phase — hence cell-cycle-nonspecific. Cross-linked DNA is recognized by repair machinery, and if repair fails, the cell dies.
Example: Cyclophosphamide is a prodrug — it's inactive until the liver's cytochrome P450 system converts it to its active alkylating metabolites. This is why patients with liver dysfunction may need dose adjustment, and why co-administered enzyme inducers or inhibitors can change its potency.
Real-world example: Cyclophosphamide is a backbone drug in CHOP regimen for non-Hodgkin lymphoma and in lupus nephritis (immunosuppressive dosing). A classic complication is hemorrhagic cystitis, caused by acrolein, a toxic metabolite that irritates the bladder urothelium. This is prevented by mesna, a thiol compound that binds and inactivates acrolein in the urine, plus aggressive hydration.
Why it matters: Alkylating agents are workhorses across solid tumors and hematologic malignancies precisely because they don't require actively dividing cells — useful against slow-growing tumors with a low growth fraction.
Common misunderstanding: Students often assume all chemotherapy toxicity comes from "killing fast cells," but alkylator-specific toxicities (hemorrhagic cystitis from cyclophosphamide, nephrotoxicity and ototoxicity from cisplatin, pulmonary fibrosis from busulfan) come from the chemical reactivity of the alkylating group itself, not simply from cell-cycle effects.
Cisplatin specifics worth knowing: forms platinum-DNA cross-links (technically not a classic alkylator but grouped with them functionally). Dose-limiting toxicity is nephrotoxicity (proximal tubule damage) — prevented with aggressive IV hydration — plus significant ototoxicity and peripheral neuropathy. Amifostine can be used as a nephroprotectant.
Antimetabolites
Definition: Antimetabolites are structural analogs of normal metabolic building blocks (folate, purines, pyrimidines). They get incorporated into metabolic pathways in place of the real molecule and either jam an enzyme or get built into faulty DNA/RNA.
Explanation: Because they interfere with DNA synthesis, they only kill cells actively in S-phase — making them classic cell-cycle-specific agents.
- Methotrexate: a folate analog that inhibits dihydrofolate reductase (DHFR), blocking regeneration of tetrahydrofolate, which is needed to make purines and thymidylate. No THF means no new DNA.
- 5-Fluorouracil (5-FU): a pyrimidine analog converted to FdUMP, which inhibits thymidylate synthase — same downstream effect, blocked thymidylate synthesis.
- 6-Mercaptopurine (6-MP): a purine analog that blocks de novo purine synthesis; metabolized by TPMT, so patients with low TPMT activity are at high risk of severe myelosuppression.
- Cytarabine (Ara-C): incorporated directly into DNA, terminating chain elongation — key drug in AML induction.
Example: A patient on high-dose methotrexate for osteosarcoma receives leucovorin (folinic acid) rescue timed hours after the methotrexate infusion. Leucovorin is already reduced folate, so it bypasses the DHFR block and rescues normal cells — but tumor cells, which have already taken the methotrexate hit and often have impaired transport, are rescued less effectively. This is the classic "leucovorin rescue" strategy that lets oncologists use near-lethal methotrexate doses.
Real-world example: Low-dose weekly methotrexate is also used in rheumatoid arthritis and psoriasis — same DHFR mechanism, much lower dose, and folate supplementation reduces GI and hepatic side effects without abolishing the therapeutic effect.
Why it matters: Antimetabolites are central to treating rapidly proliferating cancers (leukemias, lymphomas) where a high growth fraction means more cells are vulnerable in S-phase at any given time.
Common misunderstanding: Students often confuse "folate antagonist" with "folate deficiency" — methotrexate doesn't cause folate deficiency in the dietary sense, it blocks the enzyme that activates folate. That's why the antidote is leucovorin (already-active folate), not folic acid.
Targeted Therapy
Definition: Targeted therapy drugs act against a specific molecular abnormality that drives a particular cancer, rather than nonspecifically attacking all dividing cells.
Explanation: These agents typically inhibit a mutated or overexpressed protein — a kinase, a growth factor receptor, or an immune checkpoint — that the tumor depends on for survival ("oncogene addiction"). Because normal cells don't rely on that same abnormal target, targeted agents generally spare healthy tissue better than classic cytotoxics, though they bring their own distinct toxicity profiles.
Example: Imatinib inhibits the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome translocation t(9;22) in chronic myeloid leukemia. It converted CML from a disease with a few years' median survival into one managed as a chronic condition with a pill.
Real-world example: Trastuzumab is a monoclonal antibody against HER2, used in HER2-positive breast cancer. Its signature toxicity is reversible cardiotoxicity (unlike the often-irreversible cardiotoxicity of anthracyclines), so cardiac function (ejection fraction) is monitored serially during treatment. Rituximab (anti-CD20) is central to B-cell lymphoma regimens like R-CHOP.
Why it matters: Targeted therapy represents the shift from "poison the fastest-dividing cells" to "attack the specific molecular flaw." It's testable both as pharmacology and as an integration point with oncogenesis and molecular biology.
Common misunderstanding: "Targeted" does not mean "harmless." Tyrosine kinase inhibitors cause their own toxicities (imatinib: fluid retention, GI upset; trastuzumab: cardiotoxicity), and resistance mutations (like BCR-ABL T315I) can develop, requiring next-generation drugs (dasatinib, ponatinib).
Signature Toxicities — the Exam Favorite
Almost every chemotherapy question eventually asks "which drug causes X toxicity?" These pairings are worth memorizing cold:
- Doxorubicin (and other anthracyclines) → dose-dependent, cumulative cardiotoxicity (dilated cardiomyopathy) from free-radical generation and lipid peroxidation in myocytes; dexrazoxane (an iron-chelating agent) can be given to reduce this risk in high cumulative-dose patients.
- Vincristine → peripheral neuropathy (dose-limiting, not myelosuppression) from microtubule disruption in axons; also autonomic neuropathy (constipation, paralytic ileus). Notably spares the bone marrow much more than vinblastine does.
- Bleomycin → pulmonary fibrosis, worsened by high supplemental oxygen — a key anesthesia consideration in patients with prior bleomycin exposure.
- Cisplatin → nephrotoxicity, ototoxicity, peripheral neuropathy (all dose-related; hydration reduces renal risk).
- Cyclophosphamide/ifosfamide → hemorrhagic cystitis (acrolein metabolite), prevented with mesna and hydration.
- Methotrexate → myelosuppression, mucositis, hepatotoxicity; rescued with leucovorin.
- 5-FU → myelosuppression, mucositis, and the distinctive hand-foot syndrome.
- Trastuzumab → reversible cardiotoxicity.
Key Terms
| Term | Definition |
|---|---|
| Cell-cycle-specific (CCS) agent | A chemotherapy drug that only kills cells actively passing through a particular phase of the cell cycle (commonly S or M phase). |
| Cell-cycle-nonspecific (CCNS) agent | A drug that kills cells in any phase, including resting G0 cells, usually by direct DNA damage. |
| Alkylating agent | A drug class that covalently attaches alkyl groups to DNA, causing cross-links that block replication and transcription. |
| Antimetabolite | A structural analog of a normal metabolic substrate (folate, purine, pyrimidine) that disrupts DNA/RNA synthesis. |
| Leucovorin rescue | Administration of folinic acid after high-dose methotrexate to protect normal cells from lethal antifolate toxicity. |
| Mesna | A thiol drug that binds and detoxifies acrolein, preventing cyclophosphamide/ifosfamide-induced hemorrhagic cystitis. |
| Targeted therapy | A drug designed against a specific molecular abnormality (kinase, receptor, checkpoint) that a tumor depends on for growth. |
| Growth fraction | The proportion of tumor cells actively cycling versus in G0; higher growth fraction tumors respond better to cell-cycle-specific agents. |
| Myelosuppression | Bone-marrow suppression producing neutropenia, anemia, and thrombocytopenia — the most common dose-limiting toxicity shared across most cytotoxic chemotherapy. |
| Dose-limiting toxicity (DLT) | The specific adverse effect that determines the maximum tolerable dose of a drug, distinct from its general side effects. |
Common Mistakes
Misconception 1: "All chemotherapy drugs cause the same toxicities because they all kill fast-dividing cells." Why it's wrong: While myelosuppression, mucositis, and alopecia are shared because they hit normal fast-dividing tissue, many of the most testable toxicities (cardiotoxicity, neurotoxicity, nephrotoxicity, pulmonary fibrosis) come from a drug's specific chemistry, not simply from "killing dividing cells." Correct explanation: Match the toxicity to the specific drug's mechanism — doxorubicin's cardiotoxicity comes from free-radical/iron chemistry in myocytes, vincristine's neurotoxicity comes from microtubule disruption in neurons (which don't even divide), and cisplatin's nephrotoxicity comes from direct proximal tubule injury.
Misconception 2: "Cell-cycle-specific drugs are more effective than cell-cycle-nonspecific drugs." Why it's wrong: Effectiveness depends on the tumor's growth fraction and clinical context, not on the category itself. A slow-growing solid tumor with a low growth fraction (many cells resting in G0) may respond poorly to an S-phase-specific drug because few cells are ever in S-phase at once. Correct explanation: CCS drugs work best against high-growth-fraction cancers (leukemias, lymphomas) given via prolonged/repeated exposure; CCNS drugs are useful across a broader range of tumors, including slow-growing ones, because they don't need the cell to be cycling.
Misconception 3: "Leucovorin and folic acid are interchangeable rescue agents for methotrexate toxicity." Why it's wrong: Folic acid must first be reduced by DHFR to become active — but DHFR is exactly the enzyme methotrexate is blocking, so folic acid can't rescue a cell during high-dose methotrexate therapy. Correct explanation: Leucovorin (folinic acid) is already in the reduced, active form of folate, so it bypasses the DHFR block entirely and can restore purine/thymidylate synthesis in normal cells during methotrexate rescue.
Comparison and Connections
| Feature | Cell-Cycle-Specific Agents | Cell-Cycle-Nonspecific Agents |
|---|---|---|
| Kills cells in | Only a specific phase (S or M) | Any phase, including G0 |
| Dose-response | Plateaus — more time in phase matters more than higher dose | Linear — kill fraction rises steadily with dose |
| Best schedule | Continuous infusion / repeated dosing | Single large bolus dose |
| Examples | Methotrexate, 5-FU, cytarabine, vincristine, paclitaxel | Cyclophosphamide, cisplatin, doxorubicin, busulfan |
| Best suited for | High growth-fraction tumors (leukemia, lymphoma) | Broader range, including low growth-fraction solid tumors |
| Feature | Classic Cytotoxic Chemotherapy | Targeted Therapy |
|---|---|---|
| Mechanism | Nonspecific DNA/mitosis damage | Blocks a specific molecular driver of the tumor |
| Selectivity | Low — hits all fast-dividing cells | Higher — spares cells lacking the target |
| Typical toxicity | Myelosuppression, mucositis, alopecia | Target-specific (e.g., cardiotoxicity with trastuzumab, rash with EGFR inhibitors) |
| Resistance | Multidrug resistance via efflux pumps | Point mutations in the target (e.g., BCR-ABL T315I) |
| Example pairing | Doxorubicin + cyclophosphamide (AC regimen) | Trastuzumab added to chemo in HER2+ breast cancer |
Practice Questions
Recall 1: Name two cell-cycle-specific drug classes and the phase each acts on. Answer guidance: Antimetabolites act in S-phase (block DNA synthesis); vinca alkaloids/taxanes act in M-phase (disrupt the mitotic spindle).
Recall 2: What rescue agent is given after high-dose methotrexate, and why does it work? Answer guidance: Leucovorin (folinic acid) — it's already the reduced, active form of folate, so it bypasses the DHFR block methotrexate creates and restores nucleotide synthesis in normal cells.
Understanding 1: Explain why cyclophosphamide can be given as a single large IV bolus, but methotrexate at high doses is often given as a prolonged infusion. Answer guidance: Cyclophosphamide is cell-cycle-nonspecific — its DNA cross-linking damage doesn't depend on the cell being in a particular phase, so a bolus dose works. Methotrexate is S-phase specific; a prolonged infusion increases the chance of catching more tumor cells as they pass through S-phase over time.
Understanding 2: Why does trastuzumab cause reversible cardiotoxicity while doxorubicin causes largely irreversible cardiotoxicity? Answer guidance: Doxorubicin damages myocytes through cumulative free-radical/oxidative injury that can permanently destroy cardiac myocytes (which have limited regenerative capacity). Trastuzumab blocks HER2 signaling that cardiomyocytes need for normal stress response/repair; once the drug is stopped, HER2 signaling can resume and function often recovers.
Application 1: A 50-year-old man on cyclophosphamide for lymphoma develops gross hematuria. What is the likely cause, mechanism, and preventive strategy that should have been used? Answer guidance: Hemorrhagic cystitis from acrolein, a toxic metabolite of cyclophosphamide that irritates the bladder urothelium. Prevention: mesna (binds/inactivates acrolein) plus aggressive IV hydration and frequent voiding.
Application 2: A patient receiving vincristine develops constipation, foot drop, and loss of ankle reflexes, with a normal CBC. What toxicity is this, and why is the blood count normal? Answer guidance: Vincristine-induced peripheral/autonomic neuropathy from microtubule disruption in axons. Unlike most chemotherapy, vincristine's dose-limiting toxicity is neurologic, not hematologic — it has relatively little myelosuppressive effect compared to other cytotoxics, so a normal CBC is expected and doesn't rule out significant toxicity.
Analysis 1: Compare and contrast why a slow-growing solid tumor might respond poorly to cytarabine but respond better to cisplatin. Answer guidance: Cytarabine is S-phase specific and only kills cells actively synthesizing DNA; in a slow-growing tumor with a low growth fraction, most cells sit in G0 at any moment and are untouched. Cisplatin is cell-cycle-nonspecific — it can damage DNA in resting cells too, so it doesn't depend on catching cells mid-cycle, making it more broadly effective against tumors with a low growth fraction.
Analysis 2: A patient previously treated with bleomycin for testicular cancer now needs surgery under general anesthesia. What specific precaution should the anesthesia team take, and why? Answer guidance: Avoid high concentrations of supplemental oxygen. Bleomycin causes pulmonary fibrosis through free-radical-mediated lung injury, and high FiO2 can precipitate or worsen bleomycin-induced pulmonary toxicity even years after treatment, so oxygen should be titrated to the lowest concentration that maintains adequate saturation.
FAQ
Q1: Why do chemotherapy drugs cause hair loss? Hair follicle cells are among the fastest-dividing cells in the body, second only to bone marrow and GI epithelium. Cytotoxic drugs that target rapidly dividing cells damage these follicles, causing temporary alopecia that typically reverses after treatment ends.
Q2: Why are chemotherapy drugs given in cycles rather than continuously? Cycling allows normal tissues (especially bone marrow) time to recover between doses, since normal stem cells regenerate faster than most tumor cells. The gap is calculated to let healthy tissue rebound while still suppressing tumor regrowth.
Q3: What's the difference between adjuvant and neoadjuvant chemotherapy? Adjuvant chemotherapy is given after primary treatment (usually surgery) to eliminate micrometastatic disease. Neoadjuvant chemotherapy is given before surgery to shrink a tumor and make it more resectable, and it also lets clinicians see in real time how well the tumor responds to that regimen.
Q4: Why does combination chemotherapy use drugs with different mechanisms instead of just higher doses of one drug? Combining drugs with different mechanisms and, ideally, non-overlapping toxicities produces synergistic tumor killing while spreading out the toxic burden across different organ systems, and it reduces the chance that a single resistance mutation makes the whole regimen fail.
Q5: Does targeted therapy replace the need for classic chemotherapy? Not usually. Most regimens combine targeted agents with classic cytotoxics (e.g., trastuzumab plus chemotherapy in HER2+ breast cancer) because the tumor often depends on more than one pathway, and targeted resistance mutations can emerge over time.
Quick Revision
- Chemotherapy drugs are either cell-cycle-specific (kill cells only in one phase) or cell-cycle-nonspecific (kill cells in any phase, including G0).
- CCS drugs (antimetabolites, vinca alkaloids, taxanes) work best via continuous/repeated dosing; CCNS drugs (alkylators, anthracyclines) work well as a single bolus.
- Alkylating agents cross-link DNA (e.g., cyclophosphamide, cisplatin); cyclophosphamide's hemorrhagic cystitis is prevented by mesna.
- Antimetabolites mimic folate/purines/pyrimidines to block DNA synthesis; methotrexate inhibits DHFR and is rescued by leucovorin (not folic acid).
- Doxorubicin → cumulative, often irreversible cardiotoxicity; dexrazoxane can reduce this risk.
- Vincristine → peripheral/autonomic neuropathy is dose-limiting, not myelosuppression.
- Bleomycin → pulmonary fibrosis, worsened by high supplemental oxygen.
- Cisplatin → nephrotoxicity and ototoxicity; prevent renal injury with hydration.
- Targeted therapy (imatinib, trastuzumab, rituximab) hits a specific molecular driver, generally with better selectivity but its own unique toxicity profile.
- Shared toxicities across most cytotoxic chemo: myelosuppression, mucositis, alopecia, nausea/vomiting — all from hitting normal fast-dividing tissue.
- Adjuvant chemo = after surgery (mop up micrometastases); neoadjuvant chemo = before surgery (shrink tumor, test responsiveness).
Related Topics
Prerequisites
- Basic cell cycle biology (G1, S, G2, M, G0 phases)
- DNA replication and folate metabolism
- General pharmacokinetics/pharmacodynamics principles
Related Topics
- Radiation oncology principles
- Immunotherapy and immune checkpoint inhibitors
- Oncogenesis and molecular basis of cancer (Philadelphia chromosome, HER2 amplification)
- Antimicrobial pharmacology (shares concepts of selective toxicity)
Next Topics
- Immunotherapy (checkpoint inhibitors, CAR-T cell therapy)
- Supportive oncology care (antiemetics, growth factor support, febrile neutropenia management)
- Principles of drug resistance and combination regimen design